During the last session, Prime Medicine Inc (NASDAQ:PRME)’s traded shares were 1.08 million, with the beta value of the company hitting 1.95. The 52-week high for the PRME share is $8.27, that puts it down -324.1 from that peak though still a striking 15.38% gain since the share price plummeted to a 52-week low of $1.65. The company’s market capitalization is $255.76M, and the average intraday trading volume over the past 10 days was 1.47 million shares, and the average trade volume was 1.13 million shares over the past three months.
Prime Medicine Inc (PRME) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.18. PRME has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.31.
Prime Medicine Inc (NASDAQ:PRME) trade information
The stock’s 5-day price performance is -2.50%, and it has moved by -26.42% in 30 days. Based on these gigs, the overall price performance for the year is -71.86%. The short interest in Prime Medicine Inc (NASDAQ:PRME) is 19.41 million shares and it means that shorts have 14.73 day(s) to cover.
The consensus price target of analysts on Wall Street is $17, which implies an increase of 88.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $23 respectively. As a result, PRME is trading at a discount of -1079.49% off the target high and -515.38% off the low.
Prime Medicine Inc (PRME) estimates and forecasts
In the rating firms’ projections, revenue will increase 560.21% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.43M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 3.39M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -124.13%. While earnings are projected to return 27.26% in 2025, the next five years will return 12.59% per annum.
PRME Dividends
Prime Medicine Inc is due to release its next quarterly earnings on 2025-Feb-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Prime Medicine Inc insiders own 23.91% of total outstanding shares while institutional holders control 59.05%, with the float percentage being 77.61%. ALPHABET INC. is the largest shareholder of the company, while 172.0 institutions own stock in it. As of 2024-06-30, the company held over 15.06 million shares (or 12.6375% of all shares), a total value of $77.42 million in shares.
The next largest institutional holding, with 6.13 million shares, is of ARK INVESTMENT MANAGEMENT LLC’s that is approximately 5.1404% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $31.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Prime Medicine Inc (PRME) shares are ARK Genomic Revolution ETF and ARK Innovation ETF . Data provided on Feb 28, 2025 indicates that ARK Genomic Revolution ETF owns about 2.59 shares. This amounts to just over 1.98 percent of the company’s overall shares, with a $5.05 million market value. The same data shows that the other fund manager holds slightly less at 2.17, or about 1.66% of the stock, which is worth about $4.24 million.
